Application of the target management model based on a standardized metabolic disease management center in patients with type 2 diabetes mellitus complicated with retinopathy
基于标准化代谢性疾病管理中心的目标管理模式在2型糖尿病合并视网膜病变患者中的应用

摘要

目的 分析基于标准化代谢性疾病管理中心的目标管理模式用于2型糖尿病合并视网膜病变的价值。方法 2020年7月-2022年1月本院内分泌科接诊2型糖尿病合并视网膜病变病人100名，随机均分2组。试验组采取基于标准化代谢性疾病管理中心的目标管理法，对照组行常规管理。结果 关于糖化血红蛋白、空腹血糖和餐后2h血糖，管理结束之时：试验组的数据分别是（6.74±0.82）%、（6.03±0.39）mmol/L、（8.36±1.25）mmol/L，和对照组（7.58±0.93）%、（7.24±0.48）mmol/L、（9.94±1.62）mmol/L相比更低（P＜0.05）。关于总胆固醇、三酰甘油、低密度脂蛋白胆固醇与高密度脂蛋白胆固醇，在管理结束之时：试验组的数据分别是（2.07±0.19）mmol/L、（2.17±0.24）mmol/L、（2.52±0.37）mmol/L、（3.14±0.26）mmol/L，和对照组（2.83±0.21）mmol/L、（2.81±0.49）mmol/L、（3.16±0.48）mmol/L、（3.15±0.25）mmol/L的数据相比更好（P＜0.05）。结论 2型糖尿病合并视网膜病变用基于标准化代谢性疾病管理中心的目标管理模式，血糖降低更加明显，血脂改善更为迅速。

Abstract

Objective: To analyze the value of the target management model based on the standardized metabolic disease management center for type 2 diabetes combined with retinopathy.
Methods: From July 2020 to January 2022, the Department of Endocrinology received 100 patients with type 2 diabetes and retinopathy, and were randomly divided into 2 groups. The test group adopted the target management method based on the standardized metabolic disease management center, and the control group conducted routine management.
Results: For HbA 1 c, fasting glucose and 2h postprandial glucose, at the end of management: the data were (6.74 ± 0.82)%, (6.03 ± 0.39) mmol/L, (8.36 ± 1.25) mmol/L, and lower (9.94 ± 0.48) mmol/L (P <0.05). Regarding total cholesterol, triacylglycerol, LDL cholesterol, and HDL cholesterol, At the end of the management: the data of the test group are (2.07 ± 0.19) mmol/L, (2.17 ± 0.24) mmol/L, (2.52 ± 0.37) mmol/L, (3.14 ± 0.26) mmol/L, Compared with the control group (2.83 ± 0.21) mmol/L, (2.81 ± 0.49) mmol/L, (3.16 ± 0.48) mmol/L, and (3.15 ± 0.25) mmol/L data (P <0.05).
Conclusion  : Type 2 diabetes combined with retinopathy uses the target management mode based on the standardized metabolic disease management center, with more obvious blood glucose reduction and blood lipid improvement more rapidly.